Letrozolo Eg

Letrozole, the active ingredient in Letrozolo Eg, is a aromatase inhibitor presented as a oral tablet for oral use. It treats postmenopausal hormone receptor‑positive breast cancer and is used as adjuvant therapy in early‑stage disease.

GNH USA supplies Letrozolo Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Letrozolo Eg is an aromatase inhibitor used in breast‑cancer treatment pathways.

Postmenopausal hormone‑receptor‑positive breast cancer: reduces tumor growth and recurrence. Adjuvant treatment of early‑stage breast cancer: lowers risk of disease progression. Estrogen‑dependent breast cancer: helps prevent recurrence after surgery or radiation.

Letrozolo Eg may cause a range of adverse reactions. Patients should be monitored for any new symptoms.

Common Side Effects: - Hot flashes: transient episodes of increased warmth. - Arthralgia: joint pain or stiffness. - Fatigue: generalized tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional mild pain. - Osteoporosis: reduced bone mineral density over long‑term use.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Severe liver injury: marked elevation of hepatic enzymes. - Interstitial lung disease: inflammation of lung tissue. - Cardiovascular events: increased risk of heart attack or stroke.

Before initiating Letrozolo Eg, clinicians should evaluate patient history and comorbidities.

Assess bone health: consider baseline densitometry and calcium/vitamin D supplementation. Monitor liver function: periodic testing for hepatic enzymes. Evaluate cardiovascular risk: screen for hypertension, hyperlipidaemia. Avoid use in pregnancy: Letrozole is contraindicated (Category X). Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Letrozolo Eg can interact with several medicines that affect its metabolism or hormone levels.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., fluvoxamine): may increase Letrozole exposure. - Estrogen‑containing hormone therapy: antagonises therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce Letrozole plasma concentrations. - Anticoagulants (e.g., warfarin): may require INR monitoring. - Tamoxifen: concurrent use may diminish efficacy of both agents.